Pfizer has delivered a mixed performance in its latest quarterly earnings report, beating Wall Street estimates with strong performance in established medications. However, revenue fell by 1% to $17.6 billion as sales of its Covid-19 related products continue to decline. The company reaffirmed its modest outlook for 2026, projecting revenues between $59.5 billion and $62.5 billion, which has raised concerns among investors about the impact of upcoming patent losses. Shares of Pfizer experienced a decline following these results, even as they reported better-than-expected sales in Q4.